Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models

Molecular Cancer Therapeutics

Volumn 15, Issue 5, 2016, Pages 1132-1144

  Punnoose, Elizabeth A ^a   Leverson, Joel D ^b   Peale, Franklin ^a   Boghaert, Erwin R ^b   Belmont, Lisa D ^a   Tan, Nguyen ^a   Young, Amy ^a   Mitten, Michael ^b   Ingalla, Ellen ^a   Darbonne, Walter C ^a   Oleksijew, Anatol ^b   Tapang, Paul ^b   Yue, Peng ^a   Oeh, Jason ^a   Lee, Leslie ^a   Maiga, Sophie ^c   Fairbrother, Wayne J ^a   Amiot, Martine ^c   Souers, Andrew J ^b   Sampath, Deepak ^a  

^a GENENTECH INC   (United States)

^b ABBVIE INC   (United States)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

A 1155463; A 1331852; ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 3; CASPASE 7; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG; VENETOCLAX; BIM PROTEIN; FUSED HETEROCYCLIC RINGS; PROTEIN BCL X; PROTEIN BINDING; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CELL VIABILITY; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-2-LIKE PROTEIN 11; BCL-X PROTEIN; BORTEZOMIB; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MULTIPLE MYELOMA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971406559     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0730     Document Type: Article

References (38)

1. Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 2011; 204:3-12.
2. Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood 2015; pii:blood-2015-03-575365.
3. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 12:299-310.
4. Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007; 19:488-96.
5. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15:49-63.
6. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99:1885-93.
7. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100: 194-9.
8. Gomez-Bougie P, Bataille R, Amiot M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol 2004; 34:3156-64.
9. Wuilléme-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19:1248-52.
10. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. An inhibitor of BCL-2 family proteins induces regression of solid tumors. Nature 2005; 435:677-81.
11. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. A novel BCL-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26:2374-80.
12. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, et al. ABT0737, an inhibitor of BCL-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007; 21:1549-60.
13. Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, Trieu Y, et al. The BCL-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007; 13:621-9.
14. Tse C, Shoemaker AR, Adickes J, AndersonMG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable BCL-2 family inhibitor. Cancer Res 2008; 68:3421-8.
15. Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maiga S, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011; 118:3901-10.
16. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10:389-99.
17. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67:1176-83.
18. Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressingmyeloma cells. Blood 2011; 118:1329-39.
19. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 2015; 6:e1590.
20. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. BCL- 2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14:943-51.
21. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128:1173-86.
22. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19:202-8.
23. Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, et al. The Bcl-2 specific BH3mimetic ABT-199: a promising targeted therapy for t(11; 14) multiple myeloma. Leukemia 2014; 28:210-2.
24. Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, et al.Discovery of a potent and selective BCL-XL inhibitorwith invivo activity. ACS Med Chem Lett 2014; 5:1088-93.
25. Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 2015; 7:279ra40.
26. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9:351-65.
27. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014; 4:362-75.
28. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005; 65:6282-93.
29. Gomez-Bougie P, Wuilléme-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007; 67:5418-24.
30. Gomez-Bougie P, Ménoret E, Juin P, Dousset C, Pellat-Deceunynck C, Amiot M. Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction. Biochem Biophys Res Commun 2011; 413:460-4.
31. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 2010; 66:869-80.
32. Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica 2015; 100:e302-6.
33. Chiron D, Dousset C, Brosseau C, Touzeau C, Mäǧa S, Moreau P, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget 2015; 6:8750-9.
34. Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 2014; 28: 1657-65.
35. Del Gaizo Moore V, Letai A. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 2013; 332:202-5.
36. Touzeau C, Ryan J, Guerriero JL, Moreau P, Chonghaile TN, LeGouill SL, et al. BH3-profiling identifies heterogeneous dependency on BCL-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 2016; 30:761-64.
37. Kumar S, Vij R, Kaufman J, Mikhael J, Facon T, Moreau P, et al. Phase I interim safety and efficacy of venetoclax (abt-199/gdc-0199) monotherapy for relapsed/refractory multiple myeloma. J Clin Oncol 33, 2015(suppl; abstr 8576).
38. Touzeau C, Chanan-Khan A, Roberts AW, Agarwal A, Facon T, Lebovic D, et al. Phase 1b interim results: venetoclax (abt-199/gdc-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. J Clin Oncol 33, 2015(suppl; abstr 8580).